Literature DB >> 31672253

Change in Estimated GFR and Albuminuria as End Points in Clinical Trials: A Viewpoint From the FDA.

Aliza Thompson1, Kimberly Smith2, John Lawrence3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31672253     DOI： 10.1053/j.ajkd.2019.08.007

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  7 in total

1.  Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression.

Authors:  Brendon L Neuen; Hocine Tighiouart; Hiddo J L Heerspink; Edward F Vonesh; Juhi Chaudhari; Shiyuan Miao; Tak Mao Chan; Fernando C Fervenza; Jürgen Floege; Marian Goicoechea; William G Herrington; Enyu Imai; Tazeen H Jafar; Julia B Lewis; Philip Kam-Tao Li; Francesco Locatelli; Bart D Maes; Ronald D Perrone; Manuel Praga; Annalisa Perna; Francesco P Schena; Christoph Wanner; Jack F M Wetzels; Mark Woodward; Di Xie; Tom Greene; Lesley A Inker
Journal:  J Am Soc Nephrol       Date:  2021-12-03       Impact factor: 10.121

Review 2.  Targeting inflammation for the treatment of Diabetic Kidney Disease: a five-compartment mechanistic model.

Authors:  Alexis Hofherr; Julie Williams; Li-Ming Gan; Magnus Söderberg; Pernille B L Hansen; Kevin J Woollard
Journal:  BMC Nephrol       Date:  2022-06-13       Impact factor: 2.585

Review 3.  Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.

Authors:  Ravi B Patel; Jozine M Ter Maaten; João Pedro Ferreira; Finnian R McCausland; Sanjiv J Shah; Patrick Rossignol; Scott D Solomon; Muthiah Vaduganathan; Milton Packer; Aliza Thompson; Norman Stockbridge; Faiez Zannad
Journal:  Circulation       Date:  2021-01-07       Impact factor: 29.690

Review 4.  Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.

Authors:  Lesley A Inker; Hiddo J L Heerspink; Hocine Tighiouart; Juhi Chaudhari; Shiyuan Miao; Ulysses Diva; Alex Mercer; Gerald B Appel; James V Donadio; Jürgen Floege; Philip K T Li; Bart D Maes; Francesco Locatelli; Manuel Praga; Francesco P Schena; Andrew S Levey; Tom Greene
Journal:  Am J Kidney Dis       Date:  2021-03-26       Impact factor: 11.072

5.  Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.

Authors:  Sebastiaan Camiel Goulooze; Hiddo J L Heerspink; Martijn van Noort; Nelleke Snelder; Meike Brinker; Joerg Lippert; Thomas Eissing
Journal:  Clin Pharmacokinet       Date:  2022-05-05       Impact factor: 5.577

6.  Comparison of chronic kidney disease trial designs and analysis strategies.

Authors:  John Lawrence
Journal:  Kidney Res Clin Pract       Date:  2021-03-05

Review 7.  Therapeutic trials in adult FSGS: lessons learned and the road forward.

Authors:  An S De Vriese; Jack F Wetzels; Richard J Glassock; Sanjeev Sethi; Fernando C Fervenza
Journal:  Nat Rev Nephrol       Date:  2021-05-20       Impact factor: 28.314
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.